Back to top

Image: Bigstock

Phibro Animal Health Corporation

Read MoreHide Full Article

Phibro ended the second quarter fiscal 2017 on a mixed note with its bottom line exceeding the Zacks Consensus Estimate and revenues declining marginally on a year-over-year basis. Nonetheless, Animal Health remained the key contributing business, delivering positive growth on a year-over-year basis. This apart, the company’s strong gross margin is encouraging. The reaffirmed fiscal guidance also buoys optimism. Share price of the company, which was trading above the Zacks categorized Medical Information Systems industry in the last six months, has maintained the trend following the result. However, a persistent decline in Mineral Nutrition segment sales has proved a drag. Additionally, currency headwinds, sluggish macro-economic conditions and a tough competitive scenario also continue to hurt growth.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Phibro Animal Health Corporation (PAHC) - free report >>

Published in